Marksans Pharma Share Price
324.55-7.65 (-2.30%)
+87.58% past 1 Year
Marksans Pharma is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx)
Corporate filings & documents
Announcements
Intimation of schedule of Investors Meet
2 days agoIntimation of schedule of Investors Meet
2 days agoPlease find attached the voting result of the 34th AGM
1 week agoPlease find attached the voting result of the 34th AGM
1 week agoScrutinizers Report along with voting result for the 34th AGM
1 week agoScrutinizers Report along with voting result for the 34th AGM
1 week agoProceeding of 34th Annual General Meeting of the Company held today
1 week agoProceeding of 34th Annual General Meeting of the Company held today
1 week agoPlease find attached disclosure on ESG rating
1 week agoPlease find attached disclosure on ESG rating
1 week agoTranscript of Investors/Analyst meet on Q1 FY 27 Financial Results
2 weeks agoTranscript of Investors/Analyst meet on Q1 FY 27 Financial Results
2 weeks agoAudio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial Results
3 weeks agoAudio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial Results
3 weeks agoNewspaper Publication for Unaudited Financial Results for the quarter ended June 30 2026
3 weeks agoNewspaper Publication for Unaudited Financial Results for the quarter ended June 30 2026
3 weeks agoPress Release for Financial Results Q1 FY 27
3 weeks agoPress Release for Financial Results Q1 FY 27
3 weeks agoInvestor Presentation Q1 FY 27
3 weeks agoInvestor Presentation Q1 FY 27
3 weeks agoThe Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30 2026
3 weeks agoThe Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30 2026
3 weeks agoThe Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30 2026
3 weeks agoThe Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30 2026
3 weeks agoPlease find attached newspaper publication for Annual General Meeting Notice
4 weeks agoPlease find attached newspaper publication for Annual General Meeting Notice
4 weeks agoPlease find enclosed the BRSR
1 month agoPlease find enclosed the BRSR
1 month agoPlease find attached herewith the Annual Report for the Financial Year 2025-26
1 month agoPlease find attached herewith the Annual Report for the Financial Year 2025-26
1 month agoNotice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026
1 month agoNotice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026
1 month agoIntimation of schedule for Q1FY27 Earnings Conference Call
1 month agoIntimation of schedule for Q1FY27 Earnings Conference Call
1 month agoMarksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Quarterly Results For The Quarter Ended June 30 2026
1 month agoMarksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Quarterly Results For The Quarter Ended June 30 2026
1 month agoNewspaper Publication for AGM Intimation
1 month agoNewspaper Publication for AGM Intimation
1 month agoUpdate on acquisition of 100 percent share capital of ABCnow GmbH.
1 month agoUpdate on acquisition of 100 percent share capital of ABCnow GmbH.
1 month agoSecond 100 Day Campaign - "Saksham Niveshak" Phase IV
1 month agoSecond 100 Day Campaign - "Saksham Niveshak" Phase IV
1 month agoCertificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended June 30 2026
1 month agoCertificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended June 30 2026
1 month agoMarksans Pharma signed a definitive agreement to acquire 100 percent share capital of a German based Company namely ABCnow GmbH
1 month agoMarksans Pharma signed a definitive agreement to acquire 100 percent share capital of a German based Company namely ABCnow GmbH
1 month agoPl find attached announcement related to record date for payment of dividend AGM date and dividend payment date.
2 months agoPl find attached announcement related to record date for payment of dividend AGM date and dividend payment date.
2 months agoThe Board of Directors of Marksans Pharma Limited fixed 20 August 2026 as the Record Date for payment of dividend.
2 months agoThe Board of Directors of Marksans Pharma Limited fixed 20 August 2026 as the Record Date for payment of dividend.
2 months agoAnnual reports
Concalls & investor presentations
Aug 2026
ConcallPresentation
Aug 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Nov 2024
ConcallPresentation
Nov 2024
ConcallPresentation
Aug 2024
ConcallPresentation
Aug 2024
ConcallPresentation
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Nov 2023
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Jun 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-08-20
Dividend
0.9
2025-08-01
Dividend
0.8
2024-09-17
Dividend
0.6
2023-06-07
Dividend
0.5
2022-08-19
Dividend
0.25
2021-09-15
Dividend
0.25
2020-09-22
Dividend
0.1
2019-09-19
Dividend
0.05
2018-09-19
Dividend
0.05
2017-09-19
Dividend
0.05
2016-09-22
Dividend
0.12
2015-09-23
Dividend
0.12
2014-09-18
Dividend
0.1
Company details
Registered office
11th Floor, " Grandeur " Opp. Gundecha Symphony Veera Desai Extension Road Oshiwara, Andheri (West) Mumbai Maharashtra PIN: 400053 Tel No: 022- 40012000 Fax No: 022- 40012011 / 40012099 Email: [email protected] / [email protected] Internet: www.marksanspharma.com
Registrars
Office No S6-2, 6th Floor, Pinnacle Business Park,ext to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093(old address - Bharat Tin Works building, 1st floor, Opp. Vasant Oasis, Andheri East Mumbai - 400 059Tel: + 91 21 626 38200Fax: Office No S6-2, 6th Floor, Pinnacle Business Park Next to Ahura Centre, Mahakali Caves Road Andheri (E) PIN: Tel No: 91-022-62638200 Fax No: 91-022-62638299 Email: [email protected]
Management
Harshavardhan Panigrahi, Company Secretary & Compliance Officer
Mark Saldanha, Chairman & Managing Director
Mark Saldanha, Chairman & Managing Director
Sandra Saldanha, Whole Time Director
Varddhman Vikramaditya Jain, Whole Time Director
Digant Mahesh Parikh, Non Executive Independent Director
Abhinna Sundar Mohanty, Non Executive Independent Director
Shailaja Vardhan, Non Executive Independent Director
Srinivas Mishra, Non Executive Independent Director
Sunny Sharma, Non Independent & Non Executive Director
Details
BSE 524404
NSE MARKSANS
ISIN INE750C01026